Cognito Therapeutics, Inc.

We’re excited to present multiple poster presentations for our disease-modifying therapy Spectris™ in patients with Alzheimer’s Disease, at the 17th CTAD Clinical Trials on Alzheimer's Disease conference taking place in Madrid, Spain, and online, October 29 – November 1, 2024. “We’re excited to present this new clinical data at CTAD, which demonstrates the potential of Spectris™ to preserve both brain function and structure in Alzheimer’s disease patients,” said Christian Howell, CEO of Cognito Therapeutics. “Our recruitment strategies for the HOPE trial have enabled us to evaluate a diverse and representative Alzheimer’s population, and we remain focused on advancing our novel, non-invasive disease-modifying therapy for Alzheimer’s patients.” Read the release: 👇👇 https://lnkd.in/eBmBxt4W

We presented early-stage cost-effectiveness analysis of our Spectris™ therapy for Alzheimer’s disease (AD) at the International Society for Pharmacoeconomics and Outcomes Research Europe (ISPOR Europe) 2024 Annual Meeting in Barcelona, Spain last week. “Spectris is anticipated to reduce annual care expenses by providing a durable, cost-effective option without the significant side effects and ongoing treatment costs associated with the newly approved monoclonal antibodies,” said Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics. “The data presented at ISPOR is a milestone for Cognito Therapeutics and the millions impacted by #Alzheimer’s. Spectris aims to fill a critical unmet need in AD care, by potentially providing a safe treatment that improves patient outcomes while limiting the financial burden on patients and the healthcare system.” Read our release: https://lnkd.in/es_-ghce

As we gear up for #LSIUSA25 we’re showcasing the innovators from around the globe who are selected to present in Dana Point, California. Today we’re showcasing: 1. Christian Howell — Cognito Therapeutics, Inc. → Focused on discovering and developing new device-based treatments and preventive therapies for neurodegenerative diseases including Alzheimer's disease. The company has developed a wearable headset that uses sensory stimulation to evoke gamma oscillations in the brain that have been shown to improve synaptic connections between neurons, activate microglia, and enhance the removal of pathological proteins from the brain. 2. Yossi Bar — LEM Surgical AG → Focused on creating and providing the next generation of robotic surgical systems. The company's flagship product, the Dynamis System, is a multi-arm robotic surgical system that incorporates novel navigation capabilities and has an open architecture for handling concentric tools. Dynamis is intended to be a platform technology for orthopedic and neurosurgical applications. 3. Elizabeth (Ela) Jaworski — XN Health → Focused on developing a therapeutic device to prevent and mitigate the progression of ventilator-induced lung injury in mechanically ventilated patients. Their innovative approach uses phrenic nerve stimulation via the respiratory tract to induce diaphragm contractions, aiming to enhance patient outcomes and reduce ventilator weaning times. We look forward to seeing these innovators take the stage March 17th - 21st in Dana Point. Want to see what other innovators are presenting at LSI USA ‘25? Head over to our website to see the 200+ innovators selected to present. Interested in presenting at the event? Apply to present on our website today while space is still available.

Thanks MassDevice for covering our early-stage cost-effectiveness data supporting its Spectris therapy for Alzheimer’s disease (AD). Cognito said the data underlined the treatment’s potential to enhance patient outcomes over a patient’s lifetime. “Spectris is anticipated to reduce annual care expenses by providing a durable, cost-effective option without the significant side effects and ongoing treatment costs associated with the newly approved monoclonal antibodies,” said Dr. Ralph Kern, chief medical officer. “Spectris aims to fill a critical unmet need in AD care, by potentially providing a safe treatment that improves patient outcomes while limiting the financial burden on patients and the healthcare system.” Read the article by Sean Whooley: https://lnkd.in/eeqgzBGm

Excited to present our early-stage cost-effectiveness analysis of its Spectris™ therapy for Alzheimer’s disease (AD) at the ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2024 Annual Meeting in Barcelona, Spain. An early-stage cost-effectiveness model estimated Spectris’s economic value for mild-to-moderate AD patients. It demonstrated that Spectris could be cost-effective at an acquisition cost ranging from $44,000 to $108,000, based on various efficacy scenarios and a $100,000 willingness-to-pay (WTP) threshold. The model also projects an additional life year (LY) and 1.13 quality-adjusted life years (QALYs) gained with Spectris, underlining its potential to enhance patient outcomes over a patient’s lifetime. Read the release: https://lnkd.in/es_-ghce

After reviewing applications from global leaders working to build breakthrough Medtech and Healthtech businesses, we're revealing the first 200 Innovators selected to present at LSI USA '25 this March 17th - 21st. Here’s a sneak peek at 10 of them: • Thea Wulff Olesen — Ossiform • Christian Howell — Cognito Therapeutics, Inc. • Tim Moran — Avertix Medical • Pramote Hochareon — NirvaMed, Inc. • Elizabeth (Ela) Jaworski — XN Health • Ivan Lo — Breath Diagnostics, Inc. • Greg Roche — Distalmotion • Rashmi Prakash — Aruna Revolution • James Leech — Moximed • Stuart Mitchell — Novuson Surgical Inc. With hundreds of top-tier investors and strategics already confirmed, LSI USA '25 will have a record-setting investor turnout. If you're raising capital and looking to connect with leading venture capital, private equity, and angel groups, now is the perfect time to apply to present and join the ranks of LSI Alumni who have collectively raised over $2 billion in 2024. Submit your application today on our website, and we'll get back to you within 48 hours of submission.

Countdown to ISPOR Europe! Chantal W.M. van Gils will be attending and available to discuss evidence generation, value-based care, and all things HTA. You’re invited to join her poster presentation: “Early Cost-Effectiveness of SPECTRIS Therapy (evoking gamma band oscillations) in Alzheimer’s Disease,” created in collaboration with Cognito Therapeutics, Inc.. 📍 Poster ID: EE632 🗓 Tuesday, 19th November 🕓 16:00 - 19:00 Looking forward to meeting you in Barcelona! #ISPOREurope

This week, the EOS Perspectives team explored non-invasive neuromodulation, a promising treatment option for a range of diseases, with the global non-invasive neuromodulation devices market expected to reach US$2.1 billion by 2030. - The growth is driven by the increasing prevalence of chronic pain and other neurological conditions, breakthroughs in non-invasive technology, lower cost, lower risks, and drug-free application. - The sector has seen an uptick in investments, with companies such as Nalu Medical, Inc., Avation Medical, and Cognito Therapeutics, Inc. securing funding to advance their neurostimulation technology. - Technological breakthroughs such as integrating AI and machine learning with non-invasive neuromodulation devices will likely fuel further advancements in the field. - Insufficient insurance coverage is the main challenge to the market growth, resulting in limited patient accessibility to treatments. Read more in our newest article below. #neuromodulation #cognitiveimpairment #transcranialstimulation #chronicpain #medicaldevices CEFALY Technology MagVenture Neuralace Medical Zida Therapeutics STIMVIA #perspectives #eosperspectives #eosintelligence https://lnkd.in/dwmGVDYB

Our CEO Christian Howell spoke at #BioFuture24 this week in New York about neurodegenerative disease funding and accelerating scientific breakthroughs. 🧠🧠 Joining him on the panel was Alzheimer's Drug Discovery Foundation and Altoida, Inc., moderated by Ipsos. Thanks Demy-Colton for inviting us and see you at the next event!

MassDevice covers our recent #CTAD24 results. The company reported a reduced dependence score of 56.4% over 18 months in patients with mild to moderate Alzheimer’s, preserving patient function and potentially easing caregiver burden. The findings from the Phase 2 OVERTURE trial support Spectris as a promising option in Alzheimer’s treatment. https://lnkd.in/eGkiEyyq